Cambridge Healthtech Institute’s Inaugural
Radioligand Therapies
Engineering the Next Generation of Targeted Radiopharmaceuticals
September 29 - October 1, 2026
CHI’s Inaugural Radioligand Therapies conference brings together industry leaders to explore the science and strategy driving the next generation of targeted radiopharmaceuticals. Sessions will highlight advances in engineering optimized ligands, linkers, and radionuclides to improve targeting, stability, and therapeutic index, alongside emerging biological targets, novel mechanisms of action, and rational combination approaches. The program will also address the critical challenges of clinical translation, manufacturing, and supply chain scalability required to deliver RLTs to patients globally. Finally, the conference will showcase progress in personalized dosimetry and theranostics, emphasizing data-driven approaches to optimize patient selection, treatment planning, and outcomes. Together, these topics provide a comprehensive view of how innovation across discovery and development is shaping the future of precision oncology.
Coverage will include, but is not limited to:
- Engineering optimized ligands, linkers, and radionuclides
- New targets, mechanisms, and combinations
- Clinical translation for targeted radiopharmaceuticals
- Supply chain solutions
- Personalized dosimetry and theranostics
The deadline for priority consideration is March 13, 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: